PL404379A1 - Maść - Google Patents
MaśćInfo
- Publication number
- PL404379A1 PL404379A1 PL404379A PL40437913A PL404379A1 PL 404379 A1 PL404379 A1 PL 404379A1 PL 404379 A PL404379 A PL 404379A PL 40437913 A PL40437913 A PL 40437913A PL 404379 A1 PL404379 A1 PL 404379A1
- Authority
- PL
- Poland
- Prior art keywords
- weight
- ointment
- compounds
- salts
- pure
- Prior art date
Links
- 239000002674 ointment Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000016583 Anus disease Diseases 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010002153 Anal fissure Diseases 0.000 abstract 1
- 208000009531 Fissure in Ano Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 abstract 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract 1
- 239000004327 boric acid Substances 0.000 abstract 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Maść przeznaczona jest do leczenia schorzeń odbytu, zwłaszcza szczeliny odbytu. Składa się z 0,0 - 6,0% wagowych detreomycyny, 0,0 - 4,0% wagowych hydrokortyzonu, 0,2 - 20,0% wagowych anestezyny, 2,0 - 40,0% wagowych 0,1 do 10,0 procentowego roztworu kwasu borowego oraz farmacentrycznie dopuszczalnych nośników w ilości uzupełniającej skład maści do 100% wagowych. Składniki aktywne maści mogą stanowić czyste związki chemiczne bądź farmakologicznie dopuszczalne sole tych związków, estry i ich sole w ilościach równoważnych podanym zawartościom czystych związków.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL404379A PL221790B1 (pl) | 2013-06-19 | 2013-06-19 | Maść |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL404379A PL221790B1 (pl) | 2013-06-19 | 2013-06-19 | Maść |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL404379A1 true PL404379A1 (pl) | 2014-12-22 |
| PL221790B1 PL221790B1 (pl) | 2016-05-31 |
Family
ID=52106902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL404379A PL221790B1 (pl) | 2013-06-19 | 2013-06-19 | Maść |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL221790B1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250319103A1 (en) * | 2022-05-24 | 2025-10-16 | Vetnique Labs, Llc | Compositions for treatment of anal gland disease |
-
2013
- 2013-06-19 PL PL404379A patent/PL221790B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL221790B1 (pl) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MA37400A1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| NZ709486A (en) | Solid solution compositions and use in chronic inflammation | |
| BR112015008186A2 (pt) | formulação de um anticorpo estável e de baixa viscosidade | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
| EA201492021A1 (ru) | Антительный состав | |
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2013011774A (es) | Derivados de acido 3-fenilpropionico ramificados y su uso. | |
| MX2013012725A (es) | FORMULACION PARA ANTICUERPO ANTI -A4ß7. | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| MX2015003021A (es) | Derivados de acido glicirretinico y metodos de uso de los mismos. | |
| BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
| BR112014009790A2 (pt) | composto para modulação antisense da expressão de gccr, seu uso e composição | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| BR112015007231A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
| NZ720328A (en) | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | |
| DOP2015000170A (es) | Compuestos químicos | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k |